TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24119523
Drug: Intralesional triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intralesional triamcinolone acetonide (8 mg)
Study: 19148563
Drug: Risedronate treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate treatment
Study: 16366765
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Diazepam (DZ)
Study: 11564386
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg once daily (n = 108)
Study: 11564386
Drug: Cerivastatin 0.3
Normalized name: cerivastatin 0.3 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerivastatin 0.3 mg once daily (n = 107)
Study: 11564386
Drug: Cerivastatin 0.3
Normalized name: cerivastatin 0.3 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerivastatin 0.3 mg once daily
Study: 9784902
Drug: Nicotinell (nicotine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinell (nicotine patches)
Study: 3555877
Drug: 0.06 mg
Normalized name: urea 0.06 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.06 mg X kg‐1 d‐tubo‐curarine (dTc) IV three minutes prior and normal saline IV immediately prior
Study: 3555877
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline IV three minutes prior and 1.5 mg X kg‐1 lidocaine IV immediately prior
Study: 3555877
Drug: 0.06 mg
Normalized name: urea 0.06 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.06 mg X kg‐1 dTc IV three minutes prior and 1.5 mg X kg‐1 lidocaine IV immediately prior
Study: 30146493
Drug: External expert
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: External expert consultation model (workshop, therapy manual, expert follow-up consultation)
Study: 16911730
Drug: Cue exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cue exposure therapy (CET)
Study: 17230050
Drug: Placebo psychotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo psychotherapy treatment (PPT)
Study: 15302737
Drug: Fondaparinux (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fondaparinux (2.5 mg once daily)
Study: 10225047
Drug: 3 week
Normalized name: Camrese 13 Week Extended-Day Tablet Dispenser
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 week course of 70 degrees head-up tilt for 30 min daily (Group-I)
Study: 10225047
Drug: Specific yogic
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific yogic exercises equivalent to head-up or head-down tilt for 30 min daily (Group-II)
Study: 27027501
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + AMX + MET (500 mg × 3 times daily for 3 days)
Study: 27027501
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + AMX + MET (500 mg × 3 times daily for 7 days)
Study: 23535525
Drug: ABBS±ACE‐I (Aspirin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABBS±ACE‐I (Aspirin, Beta-blockers, Statins, with/without Angiotensin-converting enzyme inhibitor) (n=513)
Study: 23535525
Drug: Aspirin (A)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (A)
Study: 17190733
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitor (ACE-I)
Study: 20883265
Drug: Mesotherapy administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesotherapy administration of meglumine antimoniate
Study: 20883265
Drug: Conventional injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional injection of meglumine antimoniate
Study: 12622937
Drug: Meropenem 500
Normalized name: meropenem 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem 500 mg every 12 hours (or 1 g every 12 hours if necessary)
Study: 12622937
Drug: Imipenem/cilastatin 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/cilastatin 500 mg/500 mg every 12 hours (or 1 g every 12 hours if necessary)
Study: 10626827
Drug: Acetate-free biofiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetate-free biofiltration (AFB) with AN69 membrane and bicarbonate solution infusion (NaHCO3 145 or 167 mEq/lt)
Study: 6452802
Drug: Amitriptyline 75
Normalized name: amitriptyline 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 75 mg nocte (increasing to 150 mg nocte)
Study: 6452802
Drug: Zimelidine 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zimelidine 100 mg nocte (increasing to 200 mg nocte)
Study: 31969173
Drug: Low-dose inhaled
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose inhaled nitric oxide (5-10 ppm)
Study: 30589351
Drug: Treatment integrity
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment integrity procedures
Study: 25644360
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no MSF, 500 mL of water)
Study: 19523094
Drug: Traditional management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional management (oral intake of clear fluids allowed after passage of flatus and regular diet with the passage of bowel movement)
Study: 17135064
Drug: Hypnosis (standardized,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypnosis (standardized, individual 8‐session hypnosis treatment)
Study: 11466161
Drug: Controlled-release lovastatin
Normalized name: lovastatin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release lovastatin 10 mg
Study: 11466161
Drug: Controlled-release lovastatin
Normalized name: lovastatin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release lovastatin 20 mg
Study: 11466161
Drug: Controlled-release lovastatin
Normalized name: lovastatin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release lovastatin 40 mg
Study: 11466161
Drug: Controlled-release lovastatin
Normalized name: lovastatin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release lovastatin 60 mg
Study: 10460956
Drug: Educational program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational program of 2 hours duration implemented twice a year
Study: 10460956
Drug: Educational program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational program plus a 0.12% chlorhexidine rinse weekly
Study: 10460956
Drug: Educational program,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational program, chlorhexidine rinse, and fluoride varnish application twice a year
Study: 290649
Drug: Stannous fluoride
Normalized name: Stannous Fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stannous fluoride compounds
Study: 290649
Drug: Placebo compounds
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo compounds
Study: 20025830
Drug: Peanut supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peanut supplementation (about 77 g) with habitual diet for 4 weeks
Study: 18367384
Drug: APTD +
Approvals — FDA: no, EMA: no, PMDA: no
Description: APTD + L-DOPA
Study: 1353933
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ridazolol
Study: 1353933
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg ridazolol
Study: 1353933
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg ridazolol
Study: 1353933
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg ridazolol
Study: 6355394
Drug: Relaxation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation therapy with spouse
Study: 6355394
Drug: Relaxation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation therapy alone
Study: 6355394
Drug: Relaxation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation therapy (both groups)
Study: 24732289
Drug: Sutezolid 600
Normalized name: Sutezolid
DrugBank: Sutezolid (DB11905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sutezolid 600 mg BID
Study: 24732289
Drug: Sutezolid 1200
Normalized name: Sutezolid
DrugBank: Sutezolid (DB11905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sutezolid 1200 mg QD
Study: 24732289
Drug: Standard 4-drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 4-drug therapy
Study: 23193905
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia with propofol‐remifentanil hydrochloride (PR)
Study: 15793649
Drug: Topical 0.2
Normalized name: coal tar topical 0.2% topical soap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.2 percent glyceryl trinitrate paste, applied to the lower anal canal, three times daily for eight weeks.
Study: 8867904
Drug: Gliclazide, 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide, 160 mg/24 h
Study: 8867904
Drug: Placebo (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (in association with standard insulin treatment)
Study: 1346491
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition plus somatostatin (group B)
Study: 1346491
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition alone (group A)
Study: 6378491
Drug: Frusemide (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide (40 mg for 3 days) with high salt intake (Na+ intake 270 mmol/day)
Study: 6378491
Drug: Frusemide (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide (40 mg for 3 days) with low salt intake (Na+ intake 20 mmol/day)
Study: 6378491
Drug: Frusemide (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide (40 mg for 3 days) with high salt intake plus captopril (25 mg/6 h)
Study: 21680809
Drug: Daily sildenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily sildenafil (50 mg)
Study: 17439902
Drug: IFNbeta treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFNbeta treatment
Study: 17439902
Drug: Any relapse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any relapse during treatment
Study: 12468916
Drug: Mega-dose methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mega-dose methylprednisolone therapy
Study: 31365800
Drug: Transfusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfusion of 30 ml per kilogram
Study: 31365800
Drug: Transfusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfusion of 20 ml per kilogram
Study: 26758026
Drug: Cognitive Orientation
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Orientation to daily Occupational Performance (CO-OP) training focused on identifying effective cognitive strategies to increase motor competence, 9 sessions of 45 min each over 9 weeks.
Study: 19965584
Drug: 1.7 g
Normalized name: Vaporizer 1.7 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.7 g DHA plus 0.6 g EPA
Study: 18182992
Drug: Lower-dose ghrelin
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-dose ghrelin (2 microg kg(‐1))
Study: 18182992
Drug: Upper-dose ghrelin
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Upper-dose ghrelin (8 microg kg(‐1))
Study: 17259127
Drug: Epi-CH (activated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epi-CH (activated charcoal-epirubicin suspension)
Study: 17259127
Drug: Control (aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (aqueous epirubicin injection)
Study: 9172969
Drug: tianeptine 37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: tianeptine 37.5 mg/day
Study: 8258031
Drug: Oral zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral zinc acetate supplementation (600 mg/day) in addition to standard therapy
Study: 8258031
Drug: Only standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only standard therapy (a diet containing 0.8 g/kg/day of protein and 90 g/day of lactulose)
Study: 3899084
Drug: Plain DTP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain DTP vaccine
Study: 3899084
Drug: Adsorbed DTP
Normalized name: DTP-348
DrugBank: DTP-348 (DB12741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adsorbed DTP vaccine
Study: 27455166
Drug: Antibiotics for
Normalized name: ANTIBIOTICS FOR TOPICAL USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics for a minimum of 5 days, stopped if body temperature was 37.8°C or less for 48 hours and no more than 1 CAP-associated sign of clinical instability.
Study: 27455166
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treatment duration determined by physicians.
Study: 18417275
Drug: Cetrorelix 10mg
Normalized name: Cetrorelix
DrugBank: Cetrorelix (DB00050)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cetrorelix 10mg every 2 weeks for 2 doses
Study: 9162304
Drug: Low-fat, high-fiber,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat, high-fiber, high-vegetable and -fruit dietary pattern (20% of total energy intake, 18 g/1000 kcal, 5-8 servings daily)
Study: 8185335
Drug: HCFU (long-term
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCFU (long-term administration after radical treatment)
Study: 8185335
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (radical treatment only)
Study: 3241278
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nifedipine and enalapril
Study: 3241278
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nifedipine with sodium restriction or hydrochlorothiazide
Study: 29404979
Drug: Hyperfractionated radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiation (HFX) of 72.0 Gy in 60 fractions given twice daily
Study: 29404979
Drug: Standard radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard radiation of 60.0 Gy in 30 fractions given once daily
Study: 19751084
Drug: Supportive-expressive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive-expressive group therapy with hypnosis plus education
Study: 17273833
Drug: Hyperbaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric bupivacaine 0.5% (15 mg)
Study: 17273833
Drug: Hyperbaric prilocaine
Normalized name: Prilocaine
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperbaric prilocaine 2% (60 mg)
Study: 14745746
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (anastrozole, tamoxifen alone or combined)
Study: 8554360
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard inpatient treatment)
Study: 2528578
Drug: Isradipine (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (7.5 mg twice daily)
Study: 329522
Drug: Sisomicin administered
Normalized name: sisomicin
DrugBank: Sisomicin (DB12604)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sisomicin administered twice daily
Study: 329522
Drug: Gentamicin administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin administered three times daily
Study: 23904282
Drug: Metreleptin administration
Normalized name: Metreleptin
DrugBank: Metreleptin (DB09046)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metreleptin administration
Study: 18819901
Drug: Local mild
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local mild hypothermia therapy (LMH group)
Study: 18819901
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment (RT group)
Study: 12707230
Drug: Transendocardial injections
Normalized name: ALCOHOL 80 mL in 100 mL TRANSENDOCARDIAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transendocardial injections of autologous mononuclear bone marrow cells (15 injections of 0.2 cc)
Study: 12707230
Drug: Transendocardial injections
Normalized name: ALCOHOL 80 mL in 100 mL TRANSENDOCARDIAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transendocardial injections of autologous mononuclear bone marrow cells
Study: 2206005
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment at a dose of 0.27 IU/kg (0.1 mg/kg) three times weekly for 6 months
Study: 2206005
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment continued for another 6 months after initial treatment
Study: 2206005
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of GH after 12 months of treatment
Study: 30687503
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplements (ONS) providing 600 kcal and 22 g protein a day
Study: 30687503
Drug: Between-meal snacks
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Between-meal snacks providing 600 kcal and 22 g protein a day
Study: 27621045
Drug: Non-LARC prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-LARC prescription methods
Study: 27052067
Drug: Alfentanil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil (10 μg/kg)
Study: 21110174
Drug: Acupoint catgut-embedding
Normalized name: CATGUT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint catgut-embedding therapy
Study: 21110174
Drug: Fufuchun Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fufuchun Capsule (control)
Study: 17425514
Drug: High-salt diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-salt diet (200 mmol sodium daily)
Study: 17425514
Drug: Low-salt diet
Normalized name: Low-energy diets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-salt diet (20 mmol sodium daily)
Study: 12160582
Drug: Conventional external
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional external irradiation with agonist analogue of gonadotropin-releasing hormone
Study: 12160582
Drug: Conventional external
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional external irradiation without agonist analogue of gonadotropin-releasing hormone
Study: 7601292
Drug: Combined alpha-
Normalized name: One-Alpha
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined alpha- and beta-adrenoceptor blocking agent
Study: 2696207
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine solution infiltration anesthesia
Study: 26732187
Drug: Intensive nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive nutritional education aimed at salt restriction to 6 g/d by nutritionists
Study: 25312265
Drug: Sufentanil (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil (0.2 μg/kg, n = 24)
Study: 16339612
Drug: Guideline-level depression
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-level depression care (antidepressant use or specialty counseling)
Study: 6139668
Drug: Heat-inactivated hepatitis
Normalized name: INFLUENZA A VIRUS A/SINGAPORE/6/86 (H1N1) ANTIGEN (HEAT INACTIVATED)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat-inactivated hepatitis B vaccine (3 micrograms of surface antigen) given at 0, 1, 2, and 5 months
Study: 31931932
Drug: Propranolol (0.5‐3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (0.5‐3 mg/Kg body weight per day)
Study: 26224232
Drug: Topical antioxidant
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antioxidant cream
Study: 24479524
Drug: Chloroquine chemoprophylaxis
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine chemoprophylaxis and three intradermal doses of aseptic, purified Plasmodium falciparum sporozoites.
Study: 24479524
Drug: Atovaquone/proguanil (Malarone®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atovaquone/proguanil (Malarone®) treatment initiated on day 11 post-CHMI.
Study: 9762658
Drug: CSF-enriched antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSF-enriched antibodies
Study: 3397807
Drug: Combination met‐hGH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination met‐hGH plus oxandrolone
Study: 31883847
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with mucosal grass pollen allergen exposure
Study: 29238967
Drug: Anabasum 5
Normalized name: Anabasum
DrugBank: Lenabasum (DB12193)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anabasum 5 mg
Study: 29238967
Drug: Anabasum 20
Normalized name: Anabasum
DrugBank: Lenabasum (DB12193)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anabasum 20 mg
Study: 28931377
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy program augmented with mobile tele-health technology (6-10 total visits over 1 year)
Study: 28931377
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy program augmented with mobile tele-health technology
Study: 26437721
Drug: Distraction and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distraction and placebo treatment
Study: 15998356
Drug: 1.2 g
Normalized name: Humidifier 1.2 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 g chitosan twice daily for 3 months
Study: 12706712
Drug: Trivalent, intranasal,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent, intranasal, live attenuated influenza virus vaccine (LAIV)
Study: 8665038
Drug: Intensive smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive smoking cessation counseling and metered-dose inhaler containing ipratropium bromide (two inhalations three times daily)